Yuchun Lee - Vertex Pharmaceuticals Independent Director

VRTX -- USA Stock  

Fiscal Quarter End: December 31, 2019  

  Director
Mr. Yuchun Lee is Independent Director of Vertex Pharmaceuticals Incorporated. Mr. Lee serves as an Executive in Residence and Partner of General Catalyst Partners, a VC firm, positions he has held since April of 2013. Mr. Lee also serves as the Chief Executive Officer of Allego, Inc. and is Executive Chairman of Clarabridge, Inc. Mr. Lee was the Vice President of IBMs Enterprise Marketing Management Group from November 2010 through January 2013. Mr. Lee cofounded Unica Corporationrationration, a provider of software and services used to automate marketing processes, in 1992, and was Unicas President andor Chief Executive Officer from 1992 through November 2010, when Unica was acquired by IBM. From 1989 to 1992, Mr. Lee was a senior consultant at Digital Equipment Corporationrationration, a supplier of general computing technology and consulting services
Age: 52  Director Since 2012  MBA    
617 341-6100  www.vrtx.com
Lee holds a B.S. and an M.S. in electrical engineering and computer science from the Massachusetts Institute of Technology and an M.B.A. from Babson College.

Management Efficiency

The company has return on total asset (ROA) of 8.3 % which means that it generated profit of $8.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 51.75 % meaning that it created $51.75 on every $100 dollars invested by stockholders.
The company currently holds 649.8 M in liabilities with Debt to Equity (D/E) ratio of 12.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Ellen HoffingPerrigo Company Plc
2008
Theodore SamuelstoPerrigo Company Plc
2017
Anupam PuriDr Reddys Laboratories Ltd
2002
Larry CordellOrigin Agritech Limited
2012
Geoffery MerszeiOrigin Agritech Limited
2016
William SteereZoetis
2013
Christine PoonRegeneron Pharmaceuticals
2010
Jeffrey SmithPerrigo Company Plc
2017
Michael BrownRegeneron Pharmaceuticals
1991
Min TangOrigin Agritech Limited
2009
Huda ZoghbiRegeneron Pharmaceuticals
2016
Robert ScullyZoetis
2013
Rolf ClassonPerrigo Company Plc
2017
Frank DAmelioZoetis
2016
Geoffrey ParkerPerrigo Company Plc
2016
Sridar IyengarDr Reddys Laboratories Ltd
2011
Shlomo YanaiPerrigo Company Plc
N/A
Arthur RyanRegeneron Pharmaceuticals
2003
J MoreauDr Reddys Laboratories Ltd
2007
Laurie BrlasPerrigo Company Plc
2016
Omkar GoswamiDr Reddys Laboratories Ltd
2000

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Did you try this?

Run World Markets Correlation Now

   

World Markets Correlation

Find global opportunities by holding instruments from different markets
All  Next Launch Module

Also Currentnly Active

Purchased few shares of
few hours ago
Traded for 1320.54
Purchased over 70 shares of
few hours ago
Traded for 35.8
Purchased few shares of
few hours ago
Traded for 180.6
Also please take a look at World Market Map. Please also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Search macroaxis.com